A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial

BACKGROUND: The current standard treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma (DLBCL) primarily consists of intensified salvage therapy and, if the disease is chemo-sensitive, high dose therapy followed with autologous stem cell transplantation. In the rituxim...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Witzens-Harig, Mathias, Memmer, Marie Luise, Dreyling, Martin, Hess, Georg
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2013
Gaiak:
Study Protocol
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3701613/
https://ncbi.nlm.nih.gov/pubmed/23799873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-308
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak